Axogen (AXGN) vs LivaNova (LIVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Axogen (AXGN) has outperformed LivaNova (LIVN) over the past year, gaining 120.0% versus a gain of 46.6%. Over five years, AXGN leads with a +165.3% price change compared with -8.9% for LIVN. LivaNova is the larger company by market cap ($4.20 billion vs $2.12 billion), about 2.0 times the size, while Axogen is growing revenue faster (+20.2% vs +10.7%).
On valuation, LivaNova trades at a lower forward P/E (16.3x vs 52.5x for Axogen). Axogen converts more of its revenue into profit, with a net margin of -7.0% versus -17.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | LIVN |
|---|---|---|
| Share price | $36.13 | $76.39 |
| Market cap | $2.12B | $4.20B |
| 1-day change | -0.14% | +0.63% |
| YTD return | +10.39% | +24.15% |
| 1-year return | +120.04% | +46.59% |
| 5-year return | +165.27% | -8.94% |
| P/E ratio (TTM) | — | 22.47 |
| Forward P/E | 52.51 | 16.31 |
| EPS (TTM) | $-0.67 | $3.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | $1.39B |
| Revenue growth (YoY) | +20.21% | +10.74% |
| Net income (latest FY) | $-15.70M | $-242.47M |
| Gross margin | 74.31% | 67.71% |
| Operating margin | -3.49% | 14.36% |
| Net margin | -6.97% | -17.47% |
| 52-week high | $52.91 | $85.76 |
| 52-week low | $15.27 | $48.82 |
| Distance from 52-week high | -31.71% | -10.93% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +48.96% | +18.54% |
| Average volume | 1.21M | 648.38K |
| Shares outstanding | 58.67M | 54.93M |
| Employees | 622 | 3,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXGN has outperformed LIVN by 73.4 percentage points over the past year.
- Axogen is more profitable, keeping -7.0 cents of every revenue dollar as net income versus -17.5 cents for LivaNova.
- Axogen grew revenue faster in its latest fiscal year (+20.21% vs +10.74%).
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About LivaNova
LIVN stock →LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,300 employees
AXGN vs LIVN FAQ
Which is bigger, Axogen or LivaNova?
LivaNova (LIVN) is larger, with a market capitalization of $4.20B compared with $2.12B for Axogen (AXGN).
Which stock has performed better over the past year, AXGN or LIVN?
AXGN returned +120.04% over the past 12 months, compared with +46.59% for LIVN (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and LivaNova in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.